2015
DOI: 10.1097/gco.0000000000000218
|View full text |Cite
|
Sign up to set email alerts
|

Amniotic fluid embolism

Abstract: Although AFE cannot be prevented, early diagnosis and intervention may lead to better outcomes for both the mother and the fetus. Clinical suspicion, traditional laboratory data, or intravascular cellular debris (demonstrated only in 50% of patients) are insufficient to make a definitive diagnosis of AFE. An evolving array of novel biomarkers may help differentiate AFE from other conditions, but none of them currently provide sufficient 'early warning' ability to make real-time impact on diagnosis and/or treat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(3 citation statements)
references
References 52 publications
0
3
0
Order By: Relevance
“…The most studied markers include elevated zinc coproporphyrin, a component of meconium, and serum sialyl-Tn, a fetal antigen present in both meconium and amniotic fluid [40,41]. Other biomarkers include decreased levels of C3, C3a, and C4, insulin-like growth factor binding protein, interleukins (IL) −6 and −8, tumor necrosis factor (TNF) alpha, endothelin, activin A and proopiomelanocortin (POMC) [42,43]. A prospective design for further studies on this pathology is difficult given its rarity and complex clinical presentation, but retrospective analyses could be performed in blood serums and/or histopathological probes stored in various biobases, and they could include novel biomarkers in order to evaluate their diagnostic accuracy and feasibility for use in clinical practice.…”
Section: Discussionmentioning
confidence: 99%
“…The most studied markers include elevated zinc coproporphyrin, a component of meconium, and serum sialyl-Tn, a fetal antigen present in both meconium and amniotic fluid [40,41]. Other biomarkers include decreased levels of C3, C3a, and C4, insulin-like growth factor binding protein, interleukins (IL) −6 and −8, tumor necrosis factor (TNF) alpha, endothelin, activin A and proopiomelanocortin (POMC) [42,43]. A prospective design for further studies on this pathology is difficult given its rarity and complex clinical presentation, but retrospective analyses could be performed in blood serums and/or histopathological probes stored in various biobases, and they could include novel biomarkers in order to evaluate their diagnostic accuracy and feasibility for use in clinical practice.…”
Section: Discussionmentioning
confidence: 99%
“…In the second stage, the patient's left ventricular function decreases and acute pulmonary edema develops in the lungs. In the third stage patients have coagulopathy, heart failure, acute lung injury and acute respiratory distress syndrome (ARDS) [8]. In addition, if the fetal is not delivered at the time of AFE, the fetal heart rate may be abnormal.…”
Section: Symptoms Of the Onset Of Amniotic Fluid Embolismmentioning
confidence: 99%
“…Amniotic fluid embolism (AFE), or anaphylactoid syndrome of pregnancy, is a proinflammatory, anaphylactic-like reaction that can occur when the amniotic fluid enters the maternal blood circulation [ 1 , 2 ]. AFE is a rare complication (with a frequency of about 1 per 10–40 thousand births), but it is one of the main causes of maternal mortality in developed countries, with a mortality rate of 20–60% [ 3 , 4 , 5 , 6 , 7 ]. Although a rare complication of pregnancy, the high rates of injury for both the mother and the newborn provide a compelling argument to gain a better understanding of the mechanism of this disease [ 3 , 6 , 7 , 8 ].…”
Section: Introductionmentioning
confidence: 99%